We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Synairgen Plc | LSE:SNG | London | Ordinary Share | GB00B0381Z20 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.105 | 2.26% | 4.755 | 4.52 | 4.99 | - | 189,060 | 16:35:30 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 0 | -17.65M | -0.0876 | -0.53 | 9.36M |
| Date | Subject | Author | Discuss |
|---|---|---|---|
| 12/8/2020 08:22 | It has been 24 days since Synairgen announced the SNG001 trial results. It only took 24 days for new global confirmed infection cases to rise from 10 million to 15 million. To add the next 5 million to get to over 20 million has been quicker than 24 days. The trial resulted in a 79 per cent reduction in severe progression and a 100 per cent drop in the death rate. While a small trial, it shows a statistical basis for assuming that the death rate could be reduced by between 79 and 100 per cent. The urgency for regulatory authorities to resolve their decision on conditional approval intensifies as each day passes. | borromini1 | |
| 12/8/2020 07:23 | petralva 12341 I read the news today, oh boy! | eggy toast |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
